Onxeo: Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board
Ceridian CEN is set be acquired after shareholders finally approved the $36 per share offer from Thomas H . Lee Partners and Fidelity National Financial FNF. We expect the deal to be completed before the end of the year.
Radiotherapy, Immunotherapy and DNA Repair Inhibitors: a Winning Combination towards the Oncology of the Future